carbamates has been researched along with Sexually Transmitted Diseases in 1 studies
Sexually Transmitted Diseases: Diseases due to or propagated by sexual contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Direct-acting antivirals effectively treat chronic hepatitis C virus (HCV) infection but there is a paucity of data on their efficacy for acute HCV, when immediate treatment could prevent onward transmission." | 6.90 | Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. ( Ammerlaan, HSM; Arends, JE; Bierman, WF; Boerekamps, A; Claassen, MAA; De Weggheleire, A; den Hollander, J; Dofferhoff, ASM; Florence, E; Hullegie, SJ; Kootstra, GJ; Lauw, FN; Leyten, EM; Popping, S; Posthouwer, D; Rijnders, BJA; Schinkel, J; Soetekouw, R; van de Vijver, DACM; van den Berk, GE; van Kasteren, ME, 2019) |
| "Direct-acting antivirals effectively treat chronic hepatitis C virus (HCV) infection but there is a paucity of data on their efficacy for acute HCV, when immediate treatment could prevent onward transmission." | 2.90 | Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. ( Ammerlaan, HSM; Arends, JE; Bierman, WF; Boerekamps, A; Claassen, MAA; De Weggheleire, A; den Hollander, J; Dofferhoff, ASM; Florence, E; Hullegie, SJ; Kootstra, GJ; Lauw, FN; Leyten, EM; Popping, S; Posthouwer, D; Rijnders, BJA; Schinkel, J; Soetekouw, R; van de Vijver, DACM; van den Berk, GE; van Kasteren, ME, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boerekamps, A | 1 |
| De Weggheleire, A | 1 |
| van den Berk, GE | 1 |
| Lauw, FN | 1 |
| Claassen, MAA | 1 |
| Posthouwer, D | 1 |
| Bierman, WF | 1 |
| Hullegie, SJ | 1 |
| Popping, S | 1 |
| van de Vijver, DACM | 1 |
| Dofferhoff, ASM | 1 |
| Kootstra, GJ | 1 |
| Leyten, EM | 1 |
| den Hollander, J | 1 |
| van Kasteren, ME | 1 |
| Soetekouw, R | 1 |
| Ammerlaan, HSM | 1 |
| Schinkel, J | 1 |
| Florence, E | 1 |
| Arends, JE | 1 |
| Rijnders, BJA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Grazoprevir (MK-5172)+ Elbasvir (MK-8742) for the Treatment of Acute Hepatitis C Genotype 1/4. The Dutch Acute HCV in HIV Study (DAHHS-2)[NCT02600325] | Phase 3 | 80 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are considered failure (NCT02600325)
Timeframe: week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Group | 75 |
Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are not considered failure (NCT02600325)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment Group | 79 |
1 trial available for carbamates and Sexually Transmitted Diseases
| Article | Year |
|---|---|
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
Topics: Acute Disease; Administration, Oral; Adult; Amides; Antiviral Agents; Belgium; Benzofurans; Carbamat | 2019 |